The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Teclistamab: BCMA-CD3 Bispecific Antibody for Multiple Myeloma

BCMA-targeted bispecific T-cell engager antibody for relapsed refractory multiple myeloma after multiple prior therapies

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Teclistamab: BCMA-CD3 Bispecific Antibody for Multiple Myeloma?

Teclistamab is FDA-approved BCMA-CD3 bispecific T-cell engager antibody for relapsed refractory multiple myeloma.

Simultaneously binds BCMA on plasma cells and CD3 on T cells redirecting T-cell cytotoxicity.

MajesTEC-1 trial showed 63% overall response rate in heavily pretreated patients.

Off-the-shelf availability contrasts with CAR-T therapy requiring patient-specific manufacturing.

Step-up dosing schedule mitigates cytokine release syndrome with subsequent weekly maintenance.

Symptoms

Cytokine release syndrome typically grade 1-2 during step-up dosing requires monitoring.
Neurotoxicity including ICANS-like syndrome requires recognition and management.
Infections including opportunistic infections require prophylaxis with antimicrobials and IVIG.
Hypogammaglobulinemia is universal requiring IVIG replacement therapy.
Cytopenias including neutropenia and thrombocytopenia require monitoring with growth factor support.

Risk Factors

Multiple myeloma after at least four prior lines of therapy including immunomodulatory drug, proteasome inhibitor, anti-CD38 antibody.
Triple-class refractory disease defines patients with very limited treatment options.
Adequate organ function and performance status required for treatment.
Prior BCMA-directed therapy may affect response but does not preclude treatment.
Active infections require resolution before initiation given immunosuppressive nature.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Multiple myeloma patients with relapsed disease after multiple prior therapies warrant teclistamab consideration.
  • Specialized myeloma center referral with experienced multidisciplinary teams optimizes outcomes.
  • Severe cytokine release syndrome, neurotoxicity, infections require urgent evaluation and management.
  • Persistent infections, cytopenias require ongoing supportive care including IVIG replacement.
  • Disease progression on teclistamab may warrant alternative bispecific antibodies or clinical trials.

Treatment Methods

01
Step-up dosing with day 1 (0.06 mg/kg), day 4 (0.3 mg/kg), day 7 (1.5 mg/kg) before maintenance.
02
Maintenance dose 1.5 mg/kg subcutaneously weekly until disease progression.
03
Hospitalization recommended for step-up doses to monitor for cytokine release syndrome.
04
Cytokine release syndrome management with tocilizumab and corticosteroids.
05
Comprehensive multidisciplinary care with experienced myeloma center, infection prophylaxis with antiviral, antibacterial, antifungal, IVIG replacement for hypogammaglobulinemia, monitoring for cytopenias with growth factor support and transfusions, active surveillance for cytokine release syndrome and neurotoxicity, weekly subcutaneous administration with possible transition to longer dosing intervals, response assessment with monoclonal protein and free light chain monitoring, salvage therapy planning at progression including alternative bispecific antibodies (talquetamab, elranatamab, cevostamab) and clinical trials, and survivorship care addressing chronic effects of immunotherapy provides optimal outcomes for patients with heavily pretreated multiple myeloma.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.